All News

The World Health Organization (WHO) has included burnout in the International Classification of Diseases, 11th Revision (ICD-11); public health officials may refuse to renew the license of the last abortion provider in Missouri, which would make the state the only one in the country without access to a legal abortion provider; organizations have announced a research initiative to identify why immunotherapy causes diabetes in some patients with cancer.

Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes.

The median lag time from first-in-human to first-in-child trials of oncology drugs that were ultimately approved by FDA is 6.5 years.

If we had a consumer-centered, market-based model that required transparency in costs and quality, accountability across the continuum with payments tied to outcomes, and real competition based on data that is made available in consumer-friendly ways, we wouldn't have the problem with surprise bills we see today.

Amarin announced that its supplemental new drug application for Vascepa has been accepted for filing and granted Priority Review designation by the FDA; civil rights groups ask a federal court to strike down an HHS "conscience" rule that may limit services covered by providers and payers that violate religious or moral beliefs; US Representive Seth Moulton, D-Massachusetts, unveils a new military mental health proposal.

Here are 5 interesting findings from the May 2019 issue of AJMC®.

Chronic obstructive pulmonary disease (COPD) is associated with shorter survival and marked differences in early stages of non-small cell lung cancer (NSCLC).

Researchers in Australia studying thunderstorm-triggered asthma suggested that ways to better stratify at-risk individuals are needed.

FDA approved alpelisib (Piqray), an oral drug to be used in combination with endocrine therapy fulvestrant for the treatment of men and postmenopausal women with hormone receptor (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following disease progression on or after an endocrine-based regimen.

The FDA approved ruxolitinib (Jakafi) for another indication, this time for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.

A study has found that 28% of men and 26% of women between the ages of 35 and 50 years have osteopenia and are at risk for osteoporosis.

The FDA approved a smartphone-controlled medical device that claims to treat migraine.

A federal judge has blocked a Mississippi law that would ban abortions 6 weeks into pregnancy; Teva Pharmaceuticals settled with state of Oklahoma for $85 million 2 days before opioid trials were set to begin; the governor of Maine has signed a bill that will remove nonmedical exemptions for vaccinations.

The analysis showed the opioid cessation rate at 18 months after surgery was 64% among those who used the pain medication before joint replacement, and 95% among those who did not.

Analysis of findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study found no association between sickle cell trait and cognitive impairment.

A study combining ruxolitinib and buparlisib in myelofibrosis showed only a modest benefit compared with ruxolitinib alone, and further studies to see if there is a synergistic effect between the 2 agents will not continue.

Spanish researchers have identified 3 biomarkers, including minimal residual disease negativity, that can help define those elderly patients with multiple myeloma (MM) who are likely to achieve long-term disease control.

Higher migraine-related costs were the top indicators of a patient having chronic migraine, according to a poster presented at ISPOR 2019.

AveXis—a Novartis company—announced that it will work with payers to implement 5-year outcomes-based agreements and novel pay-over-time options. The company also said it will offer a patient program to support affordability and access.

By 2060, an estimated 48 million people each year will die with serious health-related suffering, representing an 87% increase from 2016.

A study has identified links between osteoporosis and hypertension, coronary heart disease, and cerebral infarction.

Evobrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduced gadolinium-enhancing lesions in patients with multiple sclerosis.

https://www.pharmacytimes.org/on-demand/exploring-therapeutic-targets-of-the-beta-amyloid-pathway-to-slow-the-progression-of-alzheimer-disease

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

This week, the American Psychiatric Association released results of a public opinion survey on several key mental health issues, including how well employees can access mental health care at work.

A bipartisan group of senators has revealed healthcare legislation that would address surprise medical bills and add transparency to the rebate system; starting in January, Colorado will cap insulin prices at $100 per month; the FDA has authorized marketing of the first diagnostic test for Zika virus.

This week, the top managed care news included a study questioning the Hospital Readmissions Reduction Program; FDA issuing a warning about do-it-yourself artificial pancreas systems; measles cases reach the highest level since 1994.

After a rural syringe service program was indefinitely suspended, individuals who inject drugs had a greater risk of contracting HIV and hepatitus C virus.